ADP Ribosylation of the Specific Membrane Protein of C6 Cells by Islet-activating Protein Associated with Modification of Adenylate Cyclase Activity
Overview
Affiliations
Islet-activating protein (IAP), one of the pertussis toxins, exerted dual actions on crude membrane preparations from rat C6 glioma cells; an Mr = 41,000 membrane protein was ADP-ribosylated while GTP (and GTP-dependent isoproterenol) activation of membrane adenylate cyclase was enhanced when membranes were incubated with IaP. Both actions of IaP were dependent on the incubation time and the concentrations of NAD and IAP, and were inhibited by nicotinamide; the one action was strictly paralleled by the other in magnitude. Tryptic digestion of the Mr = 41,000 protein was markedly influenced by the presence of guanyl-5'-yl beta-gamma-imidodiphosphate or NaF, the specific ligands of the regulatory component of the adenylate cyclase system. No ADP ribosylation occurred in the membranes prepared from intact C6 cells that had been incubated with IAP, suggesting that the IAP substrate had already been ADP-ribosylated by the intracellular NAD during incubation of the intact cells. Cholera toxin catalyzed ADP ribosylation of other proteins with Mr = 45,000 and 48,000/49,000 (doublet). It is concluded that IAP, added to intact cells or isolated membranes, causes unique modification of the receptor-adenylate cyclase coupling mechanism as a result of ADP ribosylation of the Mr = 41,000 protein which is presumably one of the subunits, other than the cholera toxin substrates, of the guanine nucleotide regulatory component of the cyclase system.
The diverse landscape of AB5-type toxins.
Brown P, Ojiakor A, Chemello A, Fowler C Eng Microbiol. 2024; 3(4):100104.
PMID: 39628907 PMC: 11610972. DOI: 10.1016/j.engmic.2023.100104.
Kato N, Nakai K, Tanaka H, Fukuzawa K, Hayashi M, Aoki M Biomedicines. 2024; 12(8).
PMID: 39200192 PMC: 11351898. DOI: 10.3390/biomedicines12081727.
Tsuge H, Habuka N, Yoshida T Toxins (Basel). 2024; 16(7).
PMID: 39057953 PMC: 11281641. DOI: 10.3390/toxins16070313.
Safety assessments of recombinant DTaP vaccines developed in South Korea.
Choi G, Kang K, Kim S, Ji J, Cho G, Kang H Clin Exp Vaccine Res. 2024; 13(2):155-165.
PMID: 38752005 PMC: 11091433. DOI: 10.7774/cevr.2024.13.2.155.
Sebag S, Hao M, Qian Q, Upara C, Ding Q, Zhu M Acta Pharm Sin B. 2024; 14(4):1892-1894.
PMID: 38572116 PMC: 10985024. DOI: 10.1016/j.apsb.2024.01.002.